Cost-effectiveness of 12- and 15-year-old girls’ human papillomavirus 16/18 population-based vaccination programmes in Lithuania

Vanagas, Giedrius; Padaiga, Žilvinas; Kurtinaitis, Juozas; Logminienė, Ženeta

doi:10.1177/1403494810377684

Cited by 11 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6][7][8] The cost-effectiveness of HPV vaccination among these populations have also been well documented. [9][10][11] In China, good tolerability and cost-effectiveness of HPV vaccine has been reported among 9-15 years old males and 9-45 years old females. 12 Both the World Health Organization (WHO) and the US Food and Drug Administration (FDA) recommends the HPV vaccine to be used among men and women aged 9 through 26.…”

Section: Introductionmentioning

confidence: 99%

How university students view human papillomavirus (HPV) vaccination: A cross-sectional study in Jinan, China

Zou

Wang

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The acceptability of HPV vaccination among university students in China is not well understood. Our study was of cross-sectional study design. We collected a questionnaire about socio-demographic characteristics, knowledge of, attitude toward and acceptability of HPV vaccination. A total of 351 students were included in data analyses, among whom 47.6% were males and 70.0% aged 19-21. Only 10.3% had previously heard of HPV and 5.4% HPV vaccine. Male and female students were equally likely to accept HPV vaccine (71.8 vs 69.4%, p D 0.634) and recommend it to sexual partners (73.1 vs 76.7%, p D 0.441). The great majority of students could only afford RMB 300 (USD 50) or less for HPV vaccination. HPV vaccination acceptance was associated with being in year-one (Adjusted odds ratio (AOR) D 3.78, 95% confidence interval (CI): 2.12-6.75), being from a key university (AOR D 1.88, 95%CI: 1.07-3.31), having heard of HPV-related morbidities (AOR D 1.88, 95% CI: 1.05-3.35), being concerned about HPV-related morbidities (AOR D 2.23, 95% CI: 1.16-4.27) and believing the vaccine should be given before first sexual contact (AOR D 2.44, 95% CI: 1.38-4.29). Female students were more likely to anticipate a late uptake of HPV vaccination (p D 0.002). The relatively lower levels of HPV knowledge but higher levels of vaccine acceptance among undergraduates highlighted the need for education on the roles of sexual behaviors in HPV transmission.

show abstract

Section: Introductionmentioning

confidence: 99%

How university students view human papillomavirus (HPV) vaccination: A cross-sectional study in Jinan, China

Zou

Wang

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Currently, we have presented some evidence on how much a HPV vaccination programme would affect epidemiological changes in the Lithuanian population [14], but it is also important to understand when the possible investment to the prevention programme could generate cost savings and if the costs invested to the programme's implementation would be recovered and when.…”

Section: Introductionmentioning

confidence: 99%

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme

Vanagas

Padaiga

2012

Scand J Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…Few studies have assessed the cost effectiveness of HPV vaccination in Central and Eastern European countries [2-5]. Countries in this region tend to have less-developed cervical cancer screening programs, and subsequently have considerably higher age-standardized cervical cancer incidence rates (14.7 per 100,000, 2008) than those in Western Europe (6.9 per 100,000, 2008) or North America (5.7 per 100,000, 2008) [6].…”

Section: Introductionmentioning

confidence: 99%

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia

Uusküla

Müürsepp²,

Kawai

et al. 2013

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundThis analysis assessed the epidemiological and economic impact of quadrivalent human papillomavirus (HPV4: 6/11/16/18) vaccination in Estonia.MethodsA dynamic transmission model was used to assess the epidemiological and economic impact of the routine vaccination of 12-year-old girls with a HPV4 vaccine in preventing cervical cancer, cervical intraepithelial neoplasia (CIN) grades 1, 2 and 3 and genital warts.ResultsThe model projected that at year 100, HPV4 vaccination would lead to a reduction of HPV 16/18 related cervical cancer incidence and deaths by over 97% and the incidence of HPV 6/11 related genital warts among Estonian women and men by over 94% and 81%, respectively. The incremental cost-effectiveness ratio of the HPV4 vaccination strategy was € 4,889 per QALY gained over a time horizon of 100 years.ConclusionsRoutine vaccination of 12-year-old girls with HPV4 vaccine appears to be cost-effective in Estonia, in addition to providing both short term and long term health gains.

show abstract

Cost-effectiveness of 12- and 15-year-old girls’ human papillomavirus 16/18 population-based vaccination programmes in Lithuania

Cited by 11 publications

References 29 publications

How university students view human papillomavirus (HPV) vaccination: A cross-sectional study in Jinan, China

How university students view human papillomavirus (HPV) vaccination: A cross-sectional study in Jinan, China

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia

Contact Info

Product

Resources

About